Home › Funds › Avoro Capital Advisors LLC › OCUL
Avoro Capital Advisors LLC position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Avoro Capital Advisors LLC reported holding 12,380,300 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$95.0M, representing 0.98% of its reported portfolio and ranking #17 among its reported holdings. Avoro Capital Advisors LLC has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's OCUL position evolved
Avoro Capital Advisors LLC first disclosed a stake in OCUL in Q1 2024 at 7,148,936 shares (US$65.1M). The position peaked in Q4 2025 at 10,777,777 shares, worth US$130.8M. Across 11 filings, Avoro Capital Advisors LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 12,380,300 shares valued at US$95.0M — a reduction of -159,700 shares quarter over quarter.. Notable position changes include a 39% increase in Q3 2025 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 7.15M | $65.06M | New |
| Q2 2024 | 8.06M | $55.13M | Add |
| Q3 2024 | 8.06M | $70.12M | Hold |
| Q4 2024 | 8.06M | $68.83M | Hold |
| Q1 2025 | 8.06M | $59.08M | Hold |
| Q2 2025 | 7.40M | $68.67M | Reduce |
| Q3 2025 | 10.25M | $119.82M | Add |
| Q4 2025 | 10.78M | $130.84M | Add |
| Q1 2026 | 12.31M | $104.31M | Add |
| Q2 2026 | 12.54M | $123.14M | Add |
| Q3 2026 | 12.38M | $94.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 33 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$168.3M), Venrock Adviser, LLC (US$101.6M), SUMMER ROAD LLC (US$95.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 21.94M sh · $168.28M · Q3 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- SUMMER ROAD LLC 12.46M sh · $95.59M · Q3 2026
- Logos Global Management LP 6.00M sh · $46.02M · Q3 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.62M sh · $20.12M · Q3 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held OCUL?
Avoro Capital Advisors LLC has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Avoro Capital Advisors LLC's current position in OCUL?
As of Q3 2026, Avoro Capital Advisors LLC holds 12.38M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $94.96M, representing 0.98% of its reported portfolio and ranking #17.
Has Avoro Capital Advisors LLC been buying or selling OCUL?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in OCUL. The position peaked in Q4 2025 at 10.78M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Venrock Adviser, LLC, SUMMER ROAD LLC, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.